Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRBP Stock Forecast 2025-2026
$8.31
Current Price
$101.32M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRBP Price Targets
+778.5%
To High Target of $73.00
+381.3%
To Median Target of $40.00
+236.9%
To Low Target of $28.00
CRBP Price Momentum
-5.9%
1 Week Change
+9.8%
1 Month Change
-80.5%
1 Year Change
-29.6%
Year-to-Date Change
-86.6%
From 52W High of $61.90
+79.1%
From 52W Low of $4.64
📊 TOP ANALYST CALLS
Did CRBP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Corbus is one of their latest high-conviction picks.
Latest CRBP Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CRBP has a bullish consensus with a median price target of $40.00 (ranging from $28.00 to $73.00). Currently trading at $8.31, the median forecast implies a 381.3% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRBP Analyst Ratings
10
Buy
0
Hold
0
Sell
CRBP Price Target Range
Low
$28.00
Average
$40.00
High
$73.00
Current: $8.31
Latest CRBP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRBP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $58.00 |
| May 7, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $40.00 |
| May 7, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $56.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $50.00 |
| Mar 11, 2025 | Jefferies | Maury Raycroft | Buy | Maintains | $53.00 |
| Feb 28, 2025 | William Blair | Andy Hsieh | Outperform | Initiates | $0.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $75.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $75.00 |
| Dec 2, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $35.00 |
| Sep 23, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $80.00 |
| Sep 20, 2024 | Mizuho | Graig Suvannavejh | Outperform | Reiterates | $74.00 |
| Sep 20, 2024 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $40.00 |
| Sep 20, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $82.00 |
| Sep 20, 2024 | Wedbush | Robert Driscoll | Outperform | Maintains | $51.00 |
| Aug 28, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $82.00 |
| Aug 7, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $82.00 |
| Aug 7, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $88.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $80.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reinstates | $80.00 |
| Jul 10, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $80.00 |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Competitors
The following stocks are similar to Corbus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CRBP
Corbus Pharmaceuticals
mkt cap
108.05M
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Data
Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of $101.32M with a P/E ratio of -2.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.9%.
Valuation Metrics
Market Cap
$101.32M
Enterprise Value
$-28,611,570
P/E Ratio
-2.3x
PEG Ratio
-1.6x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+130.6%
Current Ratio
11.8x
Debt/Equity
2.2x
ROE
-44.9%
ROA
-27.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Business Model
About Corbus Pharmaceuticals Holdings, Inc.
What They Do
Develops therapies for rare inflammatory diseases.
Business Model
The company focuses on creating innovative small molecule drugs that target key pathways in inflammation and fibrosis, primarily generating revenue through the development and commercialization of these therapies. By addressing unmet medical needs in the healthcare sector, it aims to capture market share in the biopharmaceutical industry.
Additional Information
Corbus Pharmaceuticals is committed to advancing specialized therapeutic approaches for chronic and serious conditions that currently lack effective treatments, positioning itself as a key player in the biotechnology field with potential for significant medical breakthroughs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Dr. Yuval Cohen Ph.D.
Country
United States
IPO Year
2014
Website
www.corbuspharma.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Latest News & Analysis
Latest News
Quick Summary
CRBP's CRB-701 shows early promise, but all programs are in initial clinical stages. The company has a stable financial position with two years of cash but faces rising R&D costs. Market sentiment is low.
Why It Matters
CRBP's promising pipeline, particularly CRB-701, and stable finances offer potential upside, but rising R&D costs could necessitate funding, impacting future valuations amid negative market sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) CEO Yuval Cohen will present a corporate update and hold investor meetings at the Jefferies Global Healthcare Conference on June 3-5, 2025.
Why It Matters
Corbus Pharmaceuticals' CEO's participation at a major healthcare conference signals potential updates on strategy, pipeline developments, and investor engagement, influencing market perceptions and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NVO, CRBP, and SKYE are developing CBD-based therapies aimed at the growing obesity market, providing alternatives as competition increases with GLP-1 treatments.
Why It Matters
NVO, CRBP, and SKYE's CBD therapies could capture market share in the obesity sector, potentially impacting stock performance amid rising competition from GLP-1 treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Corbus Pharmaceuticals has appointed Rachelle Jacques as Chair of its Board of Directors, effective May 15, 2025. The company focuses on oncology and obesity.
Why It Matters
The appointment of Rachelle Jacques as Chair could signal strategic changes and new direction for Corbus Pharmaceuticals, potentially impacting its stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CRBP's pipeline indicates potential, but the absence of marketed products is a significant concern for investors.
Why It Matters
CRBP's unmarketed status raises uncertainty about revenue generation, impacting cash flow and stock performance, which could affect investor confidence and valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Three unconventional stocks in the cannabis sector are highlighted as potential game-changers for investors by 2025.
Why It Matters
Emerging cannabis stocks may offer significant growth potential, indicating a shift in market dynamics and investment opportunities in the sector by 2025.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CRBP Stock
What is Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a median price target of $40.00. The highest price target is $73.00 and the lowest is $28.00.
Is CRBP stock a good investment in 2025?
According to current analyst ratings, CRBP has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRBP stock?
Wall Street analysts predict CRBP stock could reach $40.00 in the next 12 months. This represents a 381.3% increase from the current price of $8.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Corbus Pharmaceuticals Holdings, Inc.'s business model?
The company focuses on creating innovative small molecule drugs that target key pathways in inflammation and fibrosis, primarily generating revenue through the development and commercialization of these therapies. By addressing unmet medical needs in the healthcare sector, it aims to capture market share in the biopharmaceutical industry.
What is the highest forecasted price for CRBP Corbus Pharmaceuticals Holdings, Inc.?
The highest price target for CRBP is $73.00 from at , which represents a 778.5% increase from the current price of $8.31.
What is the lowest forecasted price for CRBP Corbus Pharmaceuticals Holdings, Inc.?
The lowest price target for CRBP is $28.00 from at , which represents a 236.9% increase from the current price of $8.31.
What is the overall CRBP consensus from analysts for Corbus Pharmaceuticals Holdings, Inc.?
The overall analyst consensus for CRBP is bullish. Out of 12 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $40.00.
How accurate are CRBP stock price projections?
Stock price projections, including those for Corbus Pharmaceuticals Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 6:52 PM UTC